Thank you for that question. If it was covered in the Quebec plan, it would be included in here. There are some drugs identified as the more expensive ones. They're called “exceptional” medications. Typically, the patient has to meet a very strict set of eligibility criteria in order to be reimbursed. We included them in the cost. We assumed that the price discount would be applied to these drugs as well.
The only I guess exception that we made for these drugs was our assumption around increase in utilization. We assumed that drug volume will increase by 12.5% across the board, except for these drugs. With these drugs, we didn't make any increase-in-volume assumptions. The reason for this is that we assumed, because of the strict eligibility criteria in place, that just because the cost is down for the patients, they're not going to start consuming this drug more. We would assume that those strict criteria would remain intact.